{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-24-000107","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2024-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.933891+00:00","generated_at":"2026-05-29T04:07:21.932653+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Elicio Therapeutics Reports Updated Phase 1 Data for ELI-002 at ESMO Immuno-Oncology Congress 2024","bullets":["Updated Phase 1 data show 16.3-month median recurrence-free survival (mRFS) and 28.9-month median overall survival (mOS) from full study population (n=25).","Strong correlation observed between T cell response and reduced risk of progression or death.","Event-driven interim analysis from randomized Phase 2 trial of ELI-002 7P expected in first half of 2025.","ELI-002 was well-tolerated with no Grade 3/4 adverse events or dose-limiting toxicities."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-24-000107","json":"https://secwatch.observer/filing/0001601485-24-000107.json","markdown":"https://secwatch.observer/filing/0001601485-24-000107.md","text":"https://secwatch.observer/filing/0001601485-24-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000107/0001601485-24-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000107/angn-20241212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-29T04:07:21.932653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}